Skip to main content
Premium Trial:

Request an Annual Quote

Broad Institute Purchases 51 HiSeq Machines from Illumina

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Broad Institute has purchased 51 HiSeq 2000 instruments from Illumina.

The HiSeq 2000 was launched earlier this year and is the latest version of Illumina's sequencing technology, providing a variety of upgraded features over its Genome Analyzer. At the time of its launch, the firm announced that Chinese genome center BGI had ordered 128 of the new systems.

Illumina said that the HiSeq instruments will replace an equal number of Genome AnalyzerIIx systems at the Broad as the institute upgrades and expands its sequencing capacity. Illumina added that it expects to ship the systems to the Broad over the next several quarters.

"We believe that the HiSeq 2000s will significantly increase our capabilities in high-throughput genomics, as our experience with early access instruments has already produced multiple runs in excess of 250 Gb of data and yielded significant improvements in lab workflow," Robert Nicol, director of sequencing operations and technology development at the Broad Institute, said in a statement.

Illumina did not disclose the purchase price for the 51 systems.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.